International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 105-112
ANTICOAGULANT THERAPY
YAVUZ BEYAZIT1, MURAT KEKİLLİ1, İBRAHİM C. HAZNEDAROĞLU1
Hacettepe Üniv. Tıp Fak. İç Hastalıkları AD ANKARA
Keywords: anticoagulation, heparin, warfarin
Anticoagulation is a treatment with significant and life threatening complications requiring that the balance of risk and benefit be individually assessed in each patient. Venous and arterial thromboembolism are a major cause for morbidity and mortality. The pharmacologic management of venous thromboembolic disease has witnessed significant advances since oral anticoagulant and heparin therapies began to gain widespread use more than 50 years ago. Heparin and warfarin are the most widely used anticoagulants for the prophylaxis and treatment of thrombus-based diseases, but these anticoagulants, have well-known clinical limitations, such as a slow onset of action and a narrow therapeutic window.
YAVUZ BEYAZIT1, MURAT KEKİLLİ1, İBRAHİM C. HAZNEDAROĞLU1
Hacettepe Üniv. Tıp Fak. İç Hastalıkları AD ANKARA
Keywords: anticoagulation, heparin, warfarin
Anticoagulation is a treatment with significant and life threatening complications requiring that the balance of risk and benefit be individually assessed in each patient. Venous and arterial thromboembolism are a major cause for morbidity and mortality. The pharmacologic management of venous thromboembolic disease has witnessed significant advances since oral anticoagulant and heparin therapies began to gain widespread use more than 50 years ago. Heparin and warfarin are the most widely used anticoagulants for the prophylaxis and treatment of thrombus-based diseases, but these anticoagulants, have well-known clinical limitations, such as a slow onset of action and a narrow therapeutic window.